Tulobuterol

DB12248InvestigationalSmall molecule

Tulobuterol is an inhaled long-acting beta2-adrenergic receptor agonist used as a bronchodilator in the management of asthma and COPD. Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.

Mechanism: Pharmacologically active on Beta-2 adrenergic receptor
Curator reviewed
Formula / weight: C₁₂H₁₈ClNO · 227.73 g/mol (avg)

Resolves to

Compound

UNII591I9SU0F7CAS41570-61-0ChEMBLCHEMBL1159717ChEBI93856PubChem5606

Clinical / RWD

RxNorm38967ATCR03AC11ATCR03CC11

Structure

InChIKeyYREYLAVBNPACJM-UHFFFAOYSA-NSMILESCC(C)(C)NCC(O)C1=CC=CC=C1Cl

Targets

P07550ADRB2

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

673Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

2ContraindicationsEach with its own population and attribute set

6Marketed productsAcross 3 countries and 4 labellers

2ATC codesIncluding every combination product, plus 20 drug categories

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tulobuterol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account